The Translational Science Group cooperates regularly with the FDA to bring gene editing therapies to the clinic. For example, we are currently advancing a gene editing-based treatment for non-small cell lung carcinoma that is now within the late-preclinical stage. This treatment, the first where CRISPR/Cas9 is used directly in solid tumors, is currently being prepared for submission as an investigational new drug.

The focus of our precision genomics group is to identify promising genomic targets to fuel innovative CRISPR techniques and technologies. By investigating potential drug targets, and how our current research can be expanded to encompass and treat new diseases, the Translational Science Group fast-tracks the discovery and development of new disease targets and therapeutic avenues.

The Translational Science Group is pursuing innovative gene therapies and drug delivery mechanisms while expanding its suite of genome editing services and software. We generate new techniques and methods to enhance the CRISPR toolbox that gene editing scientists across the world can use to better lives and develop innovative new products.

We also offer labs worldwide the ability to jump-start their own research through the generation of custom gene edited cell lines.